文献速递脑血管病

右苯丙胺对卒中后运动恢复的影响:一项随机临床试验

Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项先导性双盲区组随机临床试验纳入64例皮质或皮质下缺血性卒中伴中重度运动缺损患者,比较右苯丙胺10mg联合物理治疗与安慰剂联合物理治疗。结果显示,两组Fugl-Meyer运动评分从基线至卒中后3个月的平均变化无总体治疗相关差异(右苯丙胺组-18.65分 vs 安慰剂组-20.83分,P=0.58),次要指标及亚组亦无差异,未发生归因于研究治疗的不良事件。

要点

  • 右苯丙胺10mg联合物理治疗与安慰剂联合物理治疗相比,未改善卒中后3个月运动功能恢复。
  • Fugl-Meyer运动评分变化两组无总体差异(右苯丙胺组-18.65分 vs 安慰剂组-20.83分,P=0.58)。
  • 研究治疗方案安全,未发生归因于研究治疗的不良事件。

核心结论

  • 与安慰剂联合物理治疗相比,右苯丙胺联合物理治疗未改善大脑半球缺血性卒中后3个月的运动功能恢复。
  • 所研究的治疗方案是安全的。

研究设计与样本

  • 先导性、双盲、区组随机临床试验,纳入来自5家康复医院或单元的皮质或皮质下缺血性卒中伴中重度运动缺损患者。
  • 2001年3月至2003年3月筛选并入组,共筛选1665例潜在参与者,随机化64例。
  • 参与者须在缺血性卒中后10至30天开始治疗,主要结局于卒中后3个月评估,分析基于意向治疗,研究分析于2015年12月31日完成。

主要发现

  • 随机分配至右苯丙胺组与安慰剂组各32例(55%为男性;中位年龄66岁;年龄范围27-91岁)。
  • Fugl-Meyer运动评分从基线至卒中后3个月的平均(SEM)变化无总体治疗相关差异(右苯丙胺组-18.65(2.27)分 vs 安慰剂组-20.83(2.94)分;P=0.58)。
  • 任何次要指标均未发现总体治疗相关差异,基于卒中部位或基线严重程度的亚组亦无差异。
  • 未发生归因于研究治疗的不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Data from animal models show that the administration of dextroamphetamine combined with task-relevant training facilitates recovery after focal brain injury. Results of clinical trials in patients with stroke have been inconsistent. OBJECTIVES: To collect data important for future studies evaluating the effect of dextroamphetamine combined with physiotherapy for improving poststroke motor recovery and to test the efficacy of the approach. DESIGN, SETTING, PARTICIPANTS: This pilot, double-blind, block-randomized clinical trial included patients with cortical or subcortical ischemic stroke and moderate or severe motor deficits from 5 rehabilitation hospitals or units. Participants were screened and enrolled from March 2001 through March 2003. The primary outcome was assessed 3 months after stroke. Study analysis was completed December 31, 2015. A total of 1665 potential participants were screened and 64 were randomized. Participants had to begin treatment 10 to 30 days after ischemic stroke. Data analysis was based on intention to treat. INTERVENTIONS: Participants were allocated to a regimen of 10 mg of dextroamphetamine (n = 32) or placebo (n = 32) combined with a 1-hour physical therapy session beginning 1 hour after drug or placebo administration every 4 days for 6 sessions in addition to standard rehabilitation. MAIN OUTCOMES AND MEASURES: The primary outcome was the difference between groups in change in Fugl-Meyer motor scores from baseline to 3 months after stroke (intention to treat with dextroamphetamine). Secondary exploratory measures included the National Institutes of Health Stroke Scale, Canadian Neurological Scale, Action Research Arm Test, modified Rankin Scale score, Functional Independence Measure, Ambulation Speed and Distance, Mini-Mental State Examination, Beck Depression Inventory, and Stroke Impact Scale. RESULTS: Among the 64 patients randomized to dextroamphetamine vs placebo (55% men; median age, 66 years; age range, 27-91 years), no overall treatment-associated difference in the mean (SEM) change in Fugl-Meyer motor scores from baseline to 3 months after stroke was noted (-18.65 [2.27] points with dextroamphetamine vs -20.83 [2.94] points with placebo; P = .58). No overall treatment-associated differences in any of the study's secondary measures and no differences in subgroups based on stroke location or baseline severity were found. No adverse events were attributed to study treatments. CONCLUSIONS AND RELEVANCE: Treatment with dextroamphetamine combined with physical therapy did not improve recovery of motor function compared with placebo combined with physical therapy as assessed 3 months after hemispheric ischemic stroke. The studied treatment regimen was safe. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01905371.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Goldstein LB, Lennihan L, Rabadi MJ, et al. Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 30167675. doi:10.1001/jamaneurol.2018.2338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。